Polymyositis Rheumatoid arthritis Mixed collagen vascular disease Pulmonary – renal syndrome in thrombotic microangiopathy Antiphospholipid syndrome Thrombotic thrombocytopenic purpura Infections Neoplasms

S. Papiris,E. Manali,I. Kalomenidis,G. Kapotsis,A. Karakatsani,C. Roussos

Abstract:

What problem does this paper attempt to address?

Indications for mechanical ventilation in adults with acute respiratory failure.

D. Pierson

2002-03-01

Respiratory Care

Abstract:Increased understanding of the mechanisms and effects of acute respiratory failure has not been accompanied by more precise criteria by which the clinician can determine when intubation should be carried out and invasive positive-pressure ventilation (IPPV) instituted in a given patient. The indications traditionally offered in reviews and textbooks have tended to be either so broad as not to be very helpful in an individual case, or of questionable clinical relevance and too cumbersome for practical use. This review updates the indications for IPPV in adult patients with acute respiratory failure by examining available evidence from clinical trials and by considering new management alternatives that have become available in the last 20 years. Indications for IPPV based on specific threshold values for P(CO2) and pH or on various indices of arterial oxygenation have generally not been validated by clinical evidence, and it is unlikely that any cutoff value would be applicable to all patients or all categories of acute respiratory failure. Stated another way, there is probably no single value for arterial P(CO2), pH, or P(O2) that by itself constitutes an indication for IPPV. Compelling face validity justifies the use of IPPV in cases of apnea or when it appears certain that respiratory arrest is about to occur. However, dyspnea, tachypnea, or the subjective impression of respiratory distress are probably not in themselves justification for emergency intubation. It should be possible to avoid IPPV and its attendant complications in many cases of acute hypercapnic respiratory failure. In acute exacerbations of chronic obstructive pulmonary disease, noninvasive positive-pressure ventilation (NPPV) should be the initial ventilation approach unless the patient has one of several specific exclusion criteria such as cardiovascular instability or severely impaired mental status. It may also be possible to avoid intubation through the use of NPPV in certain immunocompromised patients with early acute hypoxemic respiratory failure. However, in other settings of acute hypoxemic respiratory failure, such as acute lung injury and acute respiratory distress syndrome, this has not been shown. The use of IPPV may improve outcomes in patients with severe cardiogenic shock. However, IPPV has not proven to be beneficial in traumatic brain injury and flail chest, in the absence of other indications.
Mesenchymal Stem Cell Transplantation Alleviated Atherosclerosis in Systemic Lupus Erythematosus Through Reducing MDSCs

Yao Genhong,Qi Jingjing,Li Xiaojing,Tang Xiaojun,Li Wenchao,Chen Weiwei,Xia Nan,Wang Shiying,Sun Lingyun

DOI: https://doi.org/10.1186/s13287-022-03002-y

IF: 6.196

2023-01-01

Cytotherapy

Abstract:Objective: The mechanism by which mesenchymal stem cell (MSC) transplantation alleviates atherosclerosis in systemic lupus erythematosus (SLE) remains elusive. In this study, we aim to explore the efficacy and mechanism of MSC in ameliorating atherosclerosis in SLE. Methods: ApoE(-/-) and Fas(-/-) mice on the B6 background were cross-bred to generate SLE mice with atherosclerosis. Myeloid-derived suppressor cells (MDSCs) were sorted and quantified. The apoE(-/-)Fas(-/-) mice were either treated with anti-Gr antibody or injected with MDSCs. The lupus-like autoimmunity and atherosclerotic lesions were evaluated. Furthermore, the apoE(-/-)Fas(-/-) mice were transplanted with MSCs and lupus-like autoimmunity and atherosclerotic lesions were assessed. Results: MDSCs in peripheral blood, spleen, draining lymph nodes increased in apoE(-/-)Fas(-/-) mice compared with B6 mice. Moreover, the adoptive transfer of MDSCs aggravated both atherosclerosis and SLE pathologies, whereas depleting MDSCs ameliorated those pathologies in apoE(-/-)Fas(-/-) mice. MSC transplantation in apoE(-/-)Fas(-/-) mice decreased the percentage of MDSCs, alleviated the typical atherosclerotic lesions, including atherosclerotic lesions in aortae and liver, and reduced serum cholesterol, triglyceride and low-density lipoprotein levels. MSC transplantation also reduced SLE pathologies, including splenomegaly, glomerular lesions, anti-dsDNA antibody in serum, urine protein and serum creatinine. Moreover, MSC transplantation regulated the generation and function of MDSCs through secreting prostaglandin E 2 (PGE2). Conclusion: Taken together, these results indicated that the increased MDSCs contributed to atherosclerosis in SLE. MSC transplantation ameliorated the atherosclerosis and SLE through reducing MDSCs by secreting PGE2.
A CCR5-Dependent Novel Mechanism for Type 1 HIV gp120 Induced Loss of Macrophage Cell Surface CD41

T. Hewson,J. Logie,P. Simmonds,S. Howie

DOI: https://doi.org/10.4049/jimmunol.166.8.4835

2001-04-15

Abstract:Type 1 HIV gp120 is especially effective in disrupting immune cell function because it is able to cause dysregulation of both infected and uninfected cells. We report a novel CCR5-dependent mechanism of gp120-induced CD4 loss from macrophages. An M-tropic gp120, using CCR5, is able to induce 70% loss of cell surface CD4 from macrophages within an hour. This cell surface CD4 loss is more substantial and rapid than the 20% loss observed with T-tropic gp120IIIB by 3 h. The rapid and substantial CD4 loss induced by M-tropic gp120 is not observed on macrophages homozygous for the ccr5Δ32 mutation, which fail to express cell surface CCR5. We have used confocal imaging to show that gp120 and CD4 are internalized together by a process resembling receptor-mediated endocytosis, and that both proteins enter HLA-DR containing compartments of the macrophage. We have also shown by semiquantitative RT-PCR that, in response to CD4 loss from the cell surface, mRNA for CD4 is up-regulated and the intracellular pool of CD4 increases. CCR5 mRNA levels are also increased. It is proposed that internalization of self and viral protein and increased pools of intracellular CD4 could modulate Ag presentation efficiencies and have implications for the induction and maintenance of both productive immune responses and self-tolerance.
Skin-Derived Mesenchymal Stem Cells Alleviate Atherosclerosis via Modulating Macrophage Function

Qun Li,Weihong Sun,Xinwen Wang,Ke Zhang,Wenda Xi,Pingjin Gao

DOI: https://doi.org/10.5966/sctm.2015-0020

Abstract:Mesenchymal stem cells (MSCs) exhibit immunosuppressive efficacy and significantly inhibit the formation of the atherosclerosis (AS) plaque in apolipoprotein E-knockout (apoE(-/-)) mice. Of note, the largest lymphoid organ, the skin, provides a readily accessible and ideal source of tissue for the isolation of MSCs: skin-derived MSCs (S-MSCs). However, the effect and the mechanism of the therapeutic properties of S-MSCs in the progression of AS are unclear. We therefore investigated a direct effect of S-MSC treatment in the formation of atherosclerotic plaque in apoE(-/-) mice. Fifty apoE(-/-) mice were divided into four groups: the control group (AS), the S-MSC treatment group (S-MSC treatment), the nuclear factor-κB (NF-κB)(-/-)-S-MSC treatment group (KO-S-MSC treatment), and the additional S-MSC migration group. Brachiocephalic artery ultrasound biomicroscope (UBM) analysis showed that S-MSC treatment significantly reduced lesion size compared with the control groups (p < .01). Histological studies demonstrated that the plaque area of the mouse aortic arch was significantly decreased after S-MSC treatment. All alterations were dependent on NF-κB activation. After tail-vein injection, S-MSCs were capable of migrating to atherosclerotic plaque and selectively taking up residence near macrophages. S-MSC treatment reduced the release of the proinflammatory cytokine tumor necrosis factor (TNF)-α and increased the expression of the anti-inflammatory factor interleukin (IL)-10 in the atherosclerotic plaque, which was also dependent on NF-κB activation. In vitro, we found lipopolysaccharide (LPS) induced NF-κB-dependent expression of cyclooxygenase-2 (COX-2) in S-MSCs. Prostaglandin E2 (PGE2) expression was markedly increased after LPS-stimulated S-MSCs were cocultured with macrophages. LPS-stimulated macrophages produced less TNF-α/IL-1β and more IL-10 when cultured with S-MSCs, and although both were dependent upon NF-κB, the release of IL-10 was diminished if the S-MSCs were pretreated with a COX-2 inhibitor or an EP2/EP4 antagonist. Our data demonstrated that S-MSCs inhibited the formation of the atherosclerotic plaque in apoE(-/-) mice by modulating the functionality of macrophages, suggesting that S-MSCs may potentially have a role in stem cell-based therapy for AS. Significance: A combination of in vitro and in vivo experiments showed that skin-derived mesenchymal stem cells (S-MSCs) can attenuate the plaque size of atherosclerosis. This is probably because S-MSCs beneficially modulate the response of macrophages through an increased release of prostaglandin E2 acting on the EP2 and EP4 receptors of the macrophages, stimulating the production and release of the anti-inflammatory cytokine interleukin-10, and decreasing the production of proinflammatory cytokine tumor necrosis factor-α. S-MSCs inhibited the formation of the atherosclerotic plaque in apolipoprotein E-knockout mice by modulating the functionality of macrophages, and the suppressive property of S-MSCs is dependent on NF-κB signaling. This study provides direct evidence that S-MSCs have a potent immunosuppressive effect in the development of atherosclerosis in mice, suggesting that S-MSCs can easily be cultured and have similar function to bone marrow-derived MSCs, a promising cell source for stem cell-based therapies of atherosclerosis, and possibly also in transplantation.
Lyme disease: a review and an outlook for Indiana.

R. Pinger,R. Hamm,M. J. Sinsko

Abstract:
Human induced pluripotent stem cell‑derived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses

Hui Shi,Meiling Liang,Weiyan Chen,Xiuting Sun,Xiang Wang,Chenghsun Li,Yiying Yang,Zhisheng Yang,Wutao Zeng

DOI: https://doi.org/10.3892/mmr.2017.8075

Abstract:The transplantation of mesenchymal stem cells (MSCs) has been a reported method for alleviating atherosclerosis (AS). Because the availability of bone marrow‑derived MSCs (BM‑MSCs) is limited, the authors used this study to explore the use of a new type of MSC, human induced pluripotent stem cell‑derived MSCs (iPSC‑MSCs), to evaluate whether these cells could alleviate AS. iPSC‑MSCs were intravenously administered to ApoE knock out mice fed on a high‑fat diet (HFD) for 12 weeks. It was reported that systematically administering iPSC‑MSCs clearly reduced the size of plaques. In addition, the numbers of macrophages and lipids in plaques were lower in the HFD + iPSC‑MSCs group than in the HFD group. Furthermore, iPSC‑MSCs attenuated AS‑associated inflammation by decreasing the levels of inflammatory cytokines, such as tumor necrosis factor‑α and interleukin‑6, in serum. In addition, the expression of Notch1 was higher in the HFD group, and injecting iPSC‑MSCs reversed this effect. In conclusion, the current study provides the first evidence indicating that iPSC‑MSCs may be a new optional MSC‑based strategy for treating AS.
The limits and potential of community development for personal and social change.

J. Dixon

DOI: https://doi.org/10.1111/J.1753-6405.1989.TB00180.X

2010-02-12

Community Health Studies

Abstract:Some health and welfare workers are making claims for community development which are both unrealistic and misleading. By tracing the history and public policy use of community development and by defining its characteristics, much of the mystique which surrounds this intervention is eliminated. Community development is revealed in this paper to have potential in the areas of personal and planned social change. However, community development's contribution to fundamental social change is circumscribed by the nature of government sponsorship and by its very process which emphasizes parochialism and the generation of self reliance.
TNF-α Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in an Experimental Model of Atherosclerosis

Aliya Sekenova,Yelena Li,Assel Issabekova,Arman Saparov,Vyacheslav Ogay

DOI: https://doi.org/10.3390/cells12182262

IF: 6

2023-09-13

Cells

Abstract:Atherosclerosis (AS) is an inflammatory disease involving multiple factors in its initiation and development. In recent years, the potential application of mesenchymal stem cells (MSCs) for treating AS has been investigated. This study examined the effect of TNF-α preconditioning on MSCs' therapeutic efficacy in treating AS in ApoE KO mice. TNF-α-treated MSCs were administered to high-fat diet-treated ApoE KO mice. Cytokine and serum lipid levels were measured before and after treatment. Cryosections of the atherosclerotic aorta were stained with Oil-Red-O, and the relative areas of atherosclerotic lesions were measured. The level of Tregs were increased in TNF-α-MSC-treated animals compared to the MSCs group. In addition, the systemic administration of TNF-α-MSCs to ApoE KO mice reduced the level of proinflammatory cytokines such as TNF-α and IFN-γ and increased the level of the immunosuppressive IL-10 in the blood serum. Total cholesterol and LDL levels were decreased, and HDL levels were increased in the TNF-α-MSCs group of ApoE KO mice. A histological analysis showed that TNF-α-MSCs decreased the size of the atherosclerotic lesion in the aorta of ApoE KO mice by 38%, although there was no significant difference when compared with untreated MSCs. Thus, our data demonstrate that TNF-α-MSCs are more effective at treating AS than untreated MSCs.
The involving progress of MSCs based therapy in atherosclerosis

Ying Lin,Wei Zhu,Xiaomin Chen

DOI: https://doi.org/10.1186/s13287-020-01728-1

2020-06-05

Abstract:Atherosclerosis is a chronic progressive vascular inflammation characterized by lipid deposition and plaque formation, for which vascular cell dysfunction and impaired immune responses are involved. Up to now, lipid-lowering drugs remain the main therapy for treating atherosclerosis; however, the surgical or interventional therapy is often applied, and yet, morbidity and mortality of such cardiovascular disease remain high worldwide. Over the past decades, an anti-inflammatory approach has become an important therapeutic target for dealing with atherosclerosis, as altered immune responses have been regarded as an essential player in the pathological process of vascular abnormality induced by hyperlipidemia. Interestingly, mesenchymal stem cells, one type of stem cells with the capabilities of self-renewal and multi-potential, have demonstrated their unique immunomodulatory function in the various pathological process, especially in atherosclerosis. While some controversies remain regarding their therapeutic efficacy and working mechanisms, our present review aims to summarize the current research progress on stem cell-based therapy, focusing on its immunomodulatory effects on the pathogenesis of atherosclerosis and how endothelial cells, smooth muscle cells, and other immune cells are regulated by MSC-based therapy.
Purification and properties of a high-molecular-weight, alkaline exopolygalacturonase from a strain of Bacillus.

T. Kobayashi,N. Higaki,A. Suzumatsu,K. Sawada,H. Hagihara,S. Kawai,S. Ito

DOI: https://doi.org/10.1016/S0141-0229(01)00355-6

IF: 3.705

2001-07-05

Enzyme and Microbial Technology

Abstract:
Stem cell therapy targets the neointimal smooth muscle cells in experimentally induced atherosclerosis: involvement of intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)

R M Hashem,L A Rashed,R M Abdelkader,K S Hashem

DOI: https://doi.org/10.1590/1414-431X2020e10807

2021-05-24

Abstract:Smooth muscle cells (SMCs) are currently considered a central pivotal player in pathogenesis and development of atherosclerotic lesions. As consequence of vascular injury, SMCs migrate from the tunica media into the tunica intima layers where they contribute to neointimal formation by converting into foam cells and producing pro-inflammatory and oxidative stress markers. We targeted the replacement of neointimal SMCs by using the mesenchymal stem cells (MSCs) therapy in experimentally induced atherosclerosis in an attempt to improve the atherosclerotic lesion and its concomitant complications. Rats were divided into 4 groups (n=20). Control group: rats kept on a standard chow diet; atherosclerotic group: rats received the atherogenic diet; stem cells-treated group: rats were injected with CD34+ stem cells (6×106 cells in 0.5 mL PBS in rat tail vein) and maintained on the atherogenic diet; and resveratrol-treated group: rats were supplemented orally with resveratrol at a dose level 3 mg/kg per day and the atherogenic diet. After 12 weeks, rats were euthanized, blood samples were collected for separation of serum, and abdominal aortas were excised for further biochemical, molecular, and histopathological investigations. We used resveratrol, the well-established anti-atherosclerotic drug, as a benchmark to assess the efficacy of stem cell therapy. MSCs treatment revealed significant amelioration in both histopathological and biochemical patterns as evidenced by decreased foam cells formation, ICAM-1, VCAM, M-CSF, iNOS, COX-2, and TNF-α. We concluded that MSCs therapy significantly replaced the neointimal SMCs and decreased adhesion molecules as well as the oxidative and inflammatory markers in atherosclerosis.
A new bilirubin-degrading enzyme from orange peels.

T. W. Wu,G. S. Li

DOI: https://doi.org/10.1139/O88-143

1988-11-01

Abstract:A novel enzyme activity that catalyzes the degradation of unconjugated bilirubin (Bu) has been demonstrated in extracts of the peels of edible oranges. Unlike the few known bilirubin-oxidizing enzymes, the orange enzyme does not produce biliverdin as a product, does not seem to require oxygen, and has a unique absorption spectrum of its products. Even at the crude stage, the enzyme has a specific activity that is 10 and 20 times higher, respectively, than those reported for the crude or partially purified Bu-degrading enzymes from mushrooms and rat liver. The enzyme has a pH optimum near 7.5 and a Km value of 50-100 microM for Bu. The enzyme is remarkably stable, retaining over 50% activity after prolonged digestion with proteinase K or heating at 100 degrees C. Similar treatments inactivated the bilirubin oxidase from Myrothecium verrucaria MT-1. The enzyme is poorly soluble in water but can be partially solubilized with cholic acid, with a doubling in specific activity.
Preparation and use of therapeutic antibodies primarily of human origin.

E. Stiehm,M. Keller,G. Vyas

DOI: https://doi.org/10.1016/j.biologicals.2008.07.002

2008-11-01

Abstract:
Caught in action: how MSCs modulate atherosclerotic plaque

Virginia Egea

DOI: https://doi.org/10.3389/fcell.2024.1379091

IF: 5.5

2024-03-28

Frontiers in Cell and Developmental Biology

Abstract:Atherosclerosis (AS) is a medical condition marked by the stiffening and constriction of the arteries. This is caused by the accumulation of plaque, a substance made up of fat, cholesterol, calcium, and other elements present in the blood. Over time, this plaque solidifies and constricts the arteries, restricting the circulation of oxygen-rich blood to the organs and other body parts. The onset and progression of AS involve a continuous inflammatory response, including the infiltration of inflammatory cells, foam cells derived from monocytes/macrophages, and inflammatory cytokines and chemokines. Mesenchymal stromal cells ( MSCs ), a type of multipotent stem cells originating from various body tissues, have recently been demonstrated to have a protective and regulatory role in diseases involving inflammation. Consequently, the transplantation of MSCs is being proposed as a novel therapeutic strategy for atherosclerosis treatment. This mini-review intends to provide a summary of the regulatory effects of MSCs at the plaque site to lay the groundwork for therapeutic interventions.

cell biology,developmental biology
Effect of Bone Marrow Mesenchymal Stem Cells on Spleen T Lymphocyte Functions in apoE~(-/-) Mice

ZHOU Jing-hong,WANG Shao-ping,WANG Jian-an

DOI: https://doi.org/10.3969/j.issn.1009-881X.2007.03.005

2007-01-01

Abstract:Objective To study the effect of bone marrow mesenchymal stem cells(MSC) on spleen T lym-phocyte functions in apoE-/-mice.Method Rat bone marrow mesenchymal stem cells and mice splenocytes were isolated and cultured alone or in combination.Flow cytometry was used to assess the ratio of CD4+/CD8+.T lymphocyte proliferation rate was determined by non-radioactivity MTS assay,and IFNγ and IL-10 secretion by ELISA.Results Compared with wide-type C57BL/6J mice,a significant inhibition of CD4+/CD8+ ratio,T cell proliferation rate and pro-inflammatory Th1 cytokine IFNγ secretion was observed in spleen T lymphocytes of apolipoprotein E-knockout(apoE-/-) mice fed on a high cholesterol diet.MSC irradiated by 5Gy Co60,significantly attenuated concanavalin A(Con A) enhanced CD4+/CD8+ ratio,T cell infiltration and IFNγ secretion in spleen T lymphocytes.The reduction were more significant when cocultured with splenocytes from apoE-/-mice than from wide-type mice.Whereas an opposite trend was observed with regard to anti-inflammatory Th2 cytokine IL-10 level.Conclusion MSC may exert antiatherosclerotic effects through modulation of T lymphocyte functions.
Resorption und Wirkung lokal applizierter Antiallergica

G. Stüttgen

DOI: https://doi.org/10.1007/BF00588797

Abstract:
Performance Analysis of KMV-Cast with Imperfect Prior Knowledge

Xinlin Huang,X. Huan,Jun Wu,Qingquan Sun,Yingchun Yuan

DOI: https://doi.org/10.1109/GLOCOM.2016.7842128

2016-12-01

Abstract:It is predicted that the global mobile data traffic will increase nearly eightfold in the next five years, and the cloud applications will consist of 90 percent of total mobile data traffic by the end of 2019. There is no doubt that the increasing high quality video requirements and huge similar information stored in cloud servers enforce to setup a new communication paradigm. In this paper, we will take a brief review over the knowledge-enhanced mobile video broadcasting (KMV-Cast) framework, and analyze its performance with imperfect prior knowledge, which means that the prior knowledge will be transmitted through Gaussian channel. The simulation results have shown that KMV-Cast with imperfect prior knowledge performs the worst compared with the other two schemes in terms of PSNR. It indicates that the prior knowledge is very important for the video reconstruction in KMV-Cast. Meanwhile, with the SNR increasing for prior knowledge transmission, the performance still performs poor and has an optimum point.
Transplantation of skin mesenchymal stem cells attenuated AngII-induced hypertension and vascular injury

Xiangxiao Li,Weihong Sun,Wenda Xi,Weili Shen,Tong Wei,Wendong Chen,Pingjin Gao,Qun Li

DOI: https://doi.org/10.1016/j.bbrc.2018.02.180

2018-03-18

Abstract:Skin mesenchymal stem cells (S-MSCs) revealed an important immunomodulatory activity to markedly suppress the formation of the atherosclerosis (AS) plaque by modulating macrophages, and also inhibit the development of experimental autoimmune encephalomyelitis (EAE) by regulating T helper 17 (Th17) cell differentiation. Macrophages and Th17 cells play important roles in hypertension. However, it remains unclear whether S-MSCs are capable of improving angiotensin (AngII)-induced hypertension by acting on inflammatory cells. Therefore, we studied a direct effect of S-MSC treatment on an AngII-induced hypertensive mouse model. Twenty-seven C57BL/6 (WT) mice were divided into three groups: Control group (WT-NC), AngII-infused group (WT-AngII), and S-MSC treatment group (WT-AngII + S-MSCs). In contrast to WT-AngII group, systolic blood pressure (SBP) and vascular damage were strikingly attenuated after tail-vein injection of S-MSCs. Numbers of Th17 cells in mouse peripheral blood of S-MSC treated group were significantly decreased, and IL-17 mRNA and protein levels were also reduced in the aorta and serum compared with WT-AngII group. Furthermore, macrophages in S-MSC treated group were switched to a regulatory profile characterized by a low ability to produce pro-inflammatory cytokine TNF-α and a high ability to produce anti-inflammatory cytokines Arg1 and IL-10. Mechanistically, we found that S-MSCs inhibited Th17 cell differentiation and induced M2 polarization. Moreover, we found proliferation and migration of S-MSCs were elevated, and expression of CXCR4, the receptor for Stromal derivated factor -1(SDF-1), was markedly increased in lipopolysaccharide (LPS)- stimulated S-MSCs. Given that SDF-1 expression was increased in the serum and aorta in AngII- induced hypertensive mice, the immunomodulatory effects exerted by S-MSCs involved the CXCR4/SDF-1 signaling. Collectively, our data demonstrated that S-MSCs attenuated AngII-induced hypertension by inhibiting Th17 cell differentiation and by modulating macrophage M2 polarization, suggesting that S-MSCs potentially have a role in stem cell based therapy for hypertension.
Bone marrow mesenchymal stem cellsderived exosomes stabilize atherosclerosis through inhibiting pyroptosis

Zhibin Bai,Haolin Hu,Fangfang Hu,Jiajie Ji,Zhenling Ji

DOI: https://doi.org/10.1186/s12872-023-03453-y

2023-09-07

Abstract:Objectives: This study aimed to determine the effects of bone marrow mesenchymal stem cells (BMSCs)-derived exosomes (BMSC-EXO) on atherosclerosis (AS), and its related underlying mechanisms. Methods: Exosomes were isolated from mouse BMSCs, and identified by transmission electron microscopy (TEM), Nanosight (NTA), and western blot. A mouse AS model was established, and exosomes were injected into the tail vein. Total cholesterol (TC) and triglycerides (TG) were detected using their corresponding assay kits. The contents of IL-1β and IL-18 in serum were detected by ELISA. The mRNA and protein expression levels of GSDMD, Caspase1, and NLRP3 were detected by qRT-PCR and Western blot. Finally, aortic tissues in the Model and BMSC-EXO groups were sent for sequencing. Results: TEM, NTA, and western blot indicated successful isolation of exosomes. Compared with the control group, the TC, TG contents, IL-1β and IL-18 concentrations of the mice in the Model group were significantly increased; nonetheless, were significantly lower after injected with BMSC-EXO than those in the Model group (p < 0.05). Compared with the control group, the expressions of NLRP3, caspase-1 and GSDMD were significantly up-regulated in the Model group (p < 0.05), while the expressions of NLRP3, caspase-1, and GSDMD were significantly down-regulated by BMSC-EXO. By sequencing, a total of 3852 DEGs were identified between the Model and BMSC-EXO group and were significantly enriched in various biological processes and pathways related to mitochondrial function, metabolism, inflammation, and immune response. Conclusion: AS can induce pyroptosis, and BMSC-EXO can reduce inflammation and alleviate the progression of AS by inhibiting NLRP3/Caspase-1/GSDMD in the pyroptosis pathway.
Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3<SUP>+</SUP> regulatory T cells

Wenchao Li,Weiwei Chen,Saisai Huang,Genhong Yao,Xiaojun Tang,Lingyun Sun

DOI: https://doi.org/10.1002/cti2.1181

2020-01-01

Clinical & Translational Immunology

Abstract:ObjectivesMesenchymal stem cells (MSCs) have shown great potential in treating autoimmune diseases (ADs). Unlike the traditional immunosuppressants, which inadvertently impair patients' antimicrobial immunity, MSCs reduce the incidence and duration of respiratory infection. However, the underlying mechanisms are unknown. MethodsTo investigate how MSCs regulate the lung immunity and improve the defence against respiratory infection, we infected MSC-treated wild-type and lupus-prone mice with Haemophilus influenzae intranasally and determined the clearance of bacteria. Tissue damage and inflammatory cytokines were measured by H&E staining and ELISA separately. Immune cell subsets in the tissues were analysed by flow cytometry. ResultsMSC pretreatment prevented overwhelming inflammation and accelerated bacterial clearance in both wild-type and lupus-prone mice. Tregs increased dramatically in the lung after MSC treatment. Adoptive transfer of Tregs isolated from MSC-treated mice offered similar protection, while deletion of Tregs abrogated the protective effects of MSCs. The majority of the intravenously injected MSCs were engulfed by lung phagocytes, which in turn produced CXCL9 and CXCL10 and recruited tremendous CXCR3(+) Tregs into the lung. Compared with their CXCR3(-) counterparts, CXCR3(+) Tregs displayed enhanced proliferation and stronger inhibitory functions. Neutralisation of CXCL9 and CXCL10 significantly downregulated the migration of CXCR3(+) Tregs and eliminated the benefits of MSC pretreatment. ConclusionHere, we showed that by recruiting CXCR3(+) Tregs, MSC treatment restricted the overactivation of inflammatory responses and prevented severe symptoms caused by infection. By discovering this novel property of MSCs, our study sheds light on optimising long-term immunosuppressive regimen for autoimmune diseases and other immune disorders.

Polymyositis Rheumatoid arthritis Mixed collagen vascular disease Pulmonary – renal syndrome in thrombotic microangiopathy Antiphospholipid syndrome Thrombotic thrombocytopenic purpura Infections Neoplasms

Indications for mechanical ventilation in adults with acute respiratory failure.

Mesenchymal Stem Cell Transplantation Alleviated Atherosclerosis in Systemic Lupus Erythematosus Through Reducing MDSCs

A CCR5-Dependent Novel Mechanism for Type 1 HIV gp120 Induced Loss of Macrophage Cell Surface CD41

Skin-Derived Mesenchymal Stem Cells Alleviate Atherosclerosis via Modulating Macrophage Function

Lyme disease: a review and an outlook for Indiana.

Human induced pluripotent stem cell‑derived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses

The limits and potential of community development for personal and social change.

TNF-α Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in an Experimental Model of Atherosclerosis

The involving progress of MSCs based therapy in atherosclerosis

Purification and properties of a high-molecular-weight, alkaline exopolygalacturonase from a strain of Bacillus.

Stem cell therapy targets the neointimal smooth muscle cells in experimentally induced atherosclerosis: involvement of intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)

A new bilirubin-degrading enzyme from orange peels.

Preparation and use of therapeutic antibodies primarily of human origin.

Caught in action: how MSCs modulate atherosclerotic plaque

Effect of Bone Marrow Mesenchymal Stem Cells on Spleen T Lymphocyte Functions in apoE~(-/-) Mice

Resorption und Wirkung lokal applizierter Antiallergica

Performance Analysis of KMV-Cast with Imperfect Prior Knowledge

Transplantation of skin mesenchymal stem cells attenuated AngII-induced hypertension and vascular injury

Bone marrow mesenchymal stem cellsderived exosomes stabilize atherosclerosis through inhibiting pyroptosis

Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3<SUP>+</SUP> regulatory T cells